Application of a “Fit for Purpose” PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide
Conclusion: A “fit for purpose” PBPK model of enzalutamide was successfully developed using public information that recapitulated it’s observed pharmacokinetics, CYP3A4 induction potential and the potential need for dose-adjustment of co-administered CYP3A substrates.
Source: Drug Metabolism Letters - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Health | Prostate Cancer | Study | Toxicology